Recent trials have focused on targeting GBM antigens that have been well characterized in preclinical studies, such as IL13Rα2, EGFRvIII, and human epidermal growth factor receptor 2 (HER2/neu). This evidence concerns the gene IL13RA2 and glioblastoma.